Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 530 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omega-3 Fatty acids Clear all
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional

Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer

NCT04293874
View directory record Official record
Conditions
Fatigue, Depression, Pain, Sleep Disturbance, Stress, Survivorship, Breast Cancer, Dietary Habits
Interventions
Personalized Meal Plan, Dietary Omega-3LC intervention
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 1 Interventional

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

NCT01308710
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Omega-3 fatty acid (Eicosapentaenoic acid)
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Early Phase 1 Interventional

Influence of an Omega-3 SPM Supplement on Quality of Life

NCT02683850
View directory record Official record
Conditions
Chronic Pain
Interventions
Omega-3 SPM™ softgel
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
20 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Supplementation for Pediatric Migraine

NCT06899074
View directory record Official record
Conditions
Migraine
Interventions
Omega 3 Polyunsaturated Fats, Matching Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement

NCT06802068
View directory record Official record
Conditions
Supplementation in Healthy Adults to Assess Impact on Omega 3 Index and Cardiometabolic Health
Interventions
whole salmon oil, Cod liver oil
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Menlo Park, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 2:39 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)

NCT02204709
View directory record Official record
Conditions
Obesity
Interventions
2N Trout, 3N Trout, Tilapia
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
20 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT02890992
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional

Omega-3 Replacement With Krill Oil in Disease Management of SLE

NCT03626311
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dry Eye Assessment and Management: Feasibility Study

NCT01102257
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Omega-3 EFA Supplement, Olive Oil
Drug
Lead sponsor
Asbell, Penny, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 22, 2026, 2:39 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

n-3 PUFA for Vascular Cognitive Aging

NCT01953705
View directory record Official record
Conditions
Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions
Omega 3 PUFA, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
75 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men

NCT03760757
View directory record Official record
Conditions
Inflammation; Muscle
Interventions
ESPO-572®, PCSO-524®
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 22, 2026, 2:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds

NCT01823419
View directory record Official record
Conditions
Typical Development
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Years to 9 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA (marine fatty acids), Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 2:39 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acid Supplementation in Acne Patients

NCT01764308
View directory record Official record
Conditions
Acne
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

NCT02104817
View directory record Official record
Conditions
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions
Epanova® (omega-3 carboxylic acids), corn oil control
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
13,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
229
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 22, 2026, 2:39 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 22, 2026, 2:39 PM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 2:39 PM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 22, 2026, 2:39 PM EDT
Recruiting Not applicable Interventional

Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease

NCT07671872
View directory record Official record
Conditions
Crohn's Disease, Active, Crohn's Disease (CD), Diet Interventions
Interventions
Catered Anti-Inflammatory Diet, Diet Guidance for Usual Diet
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
16 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 2:39 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

NCT04386577
View directory record Official record
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 22, 2026, 2:39 PM EDT